Spruce Street Capital LP Sells 117,078 Shares of Enliven Therapeutics, Inc. $ELVN

Spruce Street Capital LP lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 26.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 329,006 shares of the company’s stock after selling 117,078 shares during the period. Enliven Therapeutics accounts for 3.1% of Spruce Street Capital LP’s investment portfolio, making the stock its 11th biggest position. Spruce Street Capital LP’s holdings in Enliven Therapeutics were worth $12,897,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ELVN. Tudor Investment Corp ET AL bought a new position in shares of Enliven Therapeutics during the third quarter valued at $334,000. Candriam S.C.A. lifted its stake in Enliven Therapeutics by 31.1% during the 1st quarter. Candriam S.C.A. now owns 594,079 shares of the company’s stock valued at $23,288,000 after acquiring an additional 141,060 shares during the period. Capricorn Fund Managers Ltd purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $14,480,000. Seven Fleet Capital Management LP bought a new stake in shares of Enliven Therapeutics in the fourth quarter worth approximately $180,000. Finally, Jennison Associates LLC bought a new stake in shares of Enliven Therapeutics in the first quarter worth approximately $12,120,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. JonesTrading increased their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. The Goldman Sachs Group boosted their target price on shares of Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, Mizuho upped their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $52.95 on Friday. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $54.88. The business has a fifty day moving average price of $45.49 and a 200-day moving average price of $37.27. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -31.71 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,018 shares of company stock valued at $1,113,888 in the last ninety days. 3.00% of the stock is currently owned by insiders.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.